UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 20, 2013

 

Skyline Medical Inc.

(Exact name of Registrant as Specified in its Charter)

 

Minnesota

(State or Other Jurisdiction of Incorporation)

 

000-54361 33-1007393
(Commission File Number) (IRS Employer Identification No.)

 

2915 Commers Drive, Suite 900

Eagan, Minnesota 55121

(Address of Principal Executive Offices and Zip Code)

 

(651) 389-4800

(Registrant’s telephone number, including area code)

 

BioDrain Medical, Inc.

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

           

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

(b) On August 20, 2013, Peter L. Morawetz, PhD, resigned as a director of Skyline Medical Inc. (f/k/a BioDrain Medical, Inc.) (the “Company”). In addition to his service on the Company’s board of directors, Dr. Morawetz served on the Company’s compensation committee.

 

In addition, on August 21, 2013, Lawrence W. Gadbaw resigned as a director and Chairman of the Board of the Company. In addition to his service on the Company’s board of directors, Mr. Gadbaw served on the Company’s audit committee.

 

The Company’s board of directors has appointed Joshua Kornberg, a current director and the Company’s Chief Executive Officer, as the interim Chairman of the Board.

 

2
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Date: August 22, 2013

 

  SKYLINE MEDICAL INC.  
       
  By: /s/ Josh Kornberg  
    Josh Kornberg  
    President and Chief Executive Officer  
       

 

3